What is TIRmed Pharma?
TIRmed Pharma is a biopharmaceutical company focused on developing novel oligonucleotide treatments. Their lead candidate is a next-generation topical cream designed for mild to moderate eczema, aiming to offer non-invasive relief by reducing itch and promoting tissue regeneration without broad immunosuppression. Founded by Prof. Anna-Lena Spetz, the company addresses a critical unmet need for effective, non-steroid alternatives in managing inflammatory skin conditions, particularly for pediatric and young adult populations. The company's commitment to advancing patient care in dermatology is supported by a seasoned team of professionals.
How much funding has TIRmed Pharma raised?
TIRmed Pharma has raised a total of $630K across 1 funding round:
Other Financing Round
$630K
Other Financing Round (2020): $630K with participation from Almi Foretags
Key Investors in TIRmed Pharma
Almi Foretags
Almi Foretags is a Swedish state-owned entity providing crucial financing in the form of loans and venture capital, alongside essential business development support. They focus on fostering sustainable growth for small and medium-sized enterprises, preparing them for future challenges through financial assistance and strategic guidance.
What's next for TIRmed Pharma?
The recent major strategic investment positions TIRmed Pharma for significant advancement in its development pipeline. This capital infusion is expected to fuel further research and development, potentially accelerating clinical trials and regulatory submissions for their innovative eczema treatment. The company's focus on non-steroid therapies aligns with a growing market demand for safer, more targeted dermatological solutions, suggesting a strong trajectory for future growth and market penetration.
See full TIRmed Pharma company page
